Dernières nouvelles pour ATRenew (NYSE:RERE) Stock

ATRenew

ATRenew Inc is a pre-owned consumer electronics transactions and services platform in China. The majority of its revenue is derived from online product sales of phones and other consumer electronics goods through its platform. The Company's principal operations and geographic markets are in the People's Republic of China.

AiHuiShou Intl

ATRenew Inc. American Depositary Shares (every three of which representing two Class A ordinary shares)

ATRenew Inc

Macro Economic Events

Politics

Economics

General

SPYB

Trump Says There Was No Classified Information In Signals Chat On Houthi Strikes, White House National Security Adviser Waltz Says Looking Into How Journalist Got Into Signal Chat

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>3M</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MMM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 8 uncommon options trades for 3M.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 50%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $98,405, and 5 are calls, for a total amount of $271,631.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $130.0 to $165.0 for 3M during the past quarter. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for 3M's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of 3M's whale trades within a strike price range from $130.0 to $165.0 in the last 30 days. </p>
<h3>3M Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742929313_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>MMM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$4.2</td>
<td>$4.05</td>
<td>$4.05</td>
<td>$165.00</td>
<td>$81.0K</td>
<td align="right">756</td>
<td align="right">637</td>
</tr>
<tr>
<td>MMM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.1</td>
<td>$4.05</td>
<td>$4.1</td>
<td>$165.00</td>
<td>$70.1K</td>
<td align="right">756</td>
<td align="right">237</td>
</tr>
<tr>
<td>MMM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$4.1</td>
<td>$4.0</td>
<td>$4.1</td>
<td>$165.00</td>
<td>$46.7K</td>
<td align="right">756</td>
<td align="right">351</td>
</tr>
<tr>
<td>MMM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$4.8</td>
<td>$3.8</td>
<td>$4.0</td>
<td>$130.00</td>
<td>$40.0K</td>
<td align="right">3</td>
<td align="right">0</td>
</tr>
<tr>
<td>MMM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$19.75</td>
<td>$19.3</td>
<td>$19.47</td>
<td>$150.00</td>
<td>$38.9K</td>
<td align="right">619</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About 3M</h3>
<p>3M, a multinational conglomerate founded in 1902, sells tens of thousands of products ranging from sponges to respirators. The firm is well known for its extensive research and development capabilities, and it is a pioneer in inventing new use cases for its proprietary technologies. 3M is organized across three business segments: safety and industrial (representing around 44% of revenue), transportation and electronics (36%), and consumer (20%). The firm recently spun off its healthcare business, now known as Solventum. Nearly half of 3M's revenue comes from outside the Americas.</p>
<p>After a thorough review of the options trading surrounding 3M, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>3M's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,270,974, the price of MMM is down by -0.1%, reaching $153.0.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 35 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for 3M</h3>
<p>In the last month, 2 experts released ratings on this stock with an average target price of $137.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; In a cautious move, an analyst from RBC Capital downgraded its rating to Underperform, setting a price target of $96.<br />
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Buy rating on 3M with a target price of $179. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest 3M options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Options

Markets

Spotlight on 3M: Analyzing the Surge in Options Activity

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>First Solar</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with FSLR, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://www.benzinga.com/pro/">Benzinga</a>'s options scanner spotted 53 uncommon options trades for First Solar.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 30% bullish and 66%, bearish.</p>
<p>Out of all of the special options we uncovered, 39 are puts, for a total amount of $8,613,633, and 14 are calls, for a total amount of $1,258,967.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $95.0 to $290.0 for First Solar over the recent three months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for First Solar's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of First Solar's whale trades within a strike price range from $95.0 to $290.0 in the last 30 days. </p>
<h3>First Solar Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742929308_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$32.0</td>
<td>$31.95</td>
<td>$32.0</td>
<td>$130.00</td>
<td>$3.2M</td>
<td>4.2K</td>
<td>2.0K</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$34.05</td>
<td>$32.0</td>
<td>$32.0</td>
<td>$130.00</td>
<td>$1.2M</td>
<td>4.2K</td>
<td>3.0K</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$3.9</td>
<td>$3.55</td>
<td>$3.75</td>
<td>$170.00</td>
<td>$375.0K</td>
<td>460</td>
<td>1.0K</td>
</tr>
<tr>
<td>FSLR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.19</td>
<td>$1.05</td>
<td>$1.16</td>
<td>$200.00</td>
<td>$336.3K</td>
<td>1.3K</td>
<td>7.1K</td>
</tr>
<tr>
<td>FSLR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$29.45</td>
<td>$28.1</td>
<td>$28.55</td>
<td>$125.00</td>
<td>$285.5K</td>
<td>160</td>
<td>100</td>
</tr>
</tbody>
</table>
</p>
<h3>About First Solar</h3>
<p>First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and India.</p>
<h3>Current Position of First Solar</h3>
<ul>
<li>With a volume of 2,136,531, the price of FSLR is up 1.9% at $131.27. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 36 days.</li>
</ul>
<h3>What The Experts Say On First Solar</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $245.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on First Solar, maintaining a target price of $238.<br />
&#x2A; Consistent in their evaluation, an analyst from Barclays keeps a Overweight rating on First Solar with a target price of $236.<br />
&#x2A; In a cautious move, an analyst from BMO Capital downgraded its rating to Outperform, setting a price target of $230.<br />
&#x2A; Maintaining their stance, an analyst from Citigroup continues to hold a Neutral rating for First Solar, targeting a price of $236.<br />
&#x2A; An analyst from UBS has decided to maintain their Buy rating on First Solar, which currently sits at a price target of $285. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for First Solar with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.</p>


FSLR

A Closer Look at First Solar's Options Market Dynamics

<p>Deep-pocketed investors have adopted a bullish approach towards Royal Caribbean Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in RCL usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 32 extraordinary options activities for Royal Caribbean Gr. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 53% leaning bullish and 40% bearish. Among these notable options, 14 are puts, totaling $797,611, and 18 are calls, amounting to $1,519,378.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $110.0 and $300.0 for Royal Caribbean Gr, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of Royal Caribbean Gr stands at 281.06, with a total volume reaching 3,881.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Royal Caribbean Gr, situated within the strike price corridor from $110.0 to $300.0, throughout the last 30 days.</p>
<h3>Royal Caribbean Gr Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742929303_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$123.6</td>
<td>$122.8</td>
<td>$122.8</td>
<td>$110.00</td>
<td>$454.3K</td>
<td align="right">8</td>
<td align="right">40</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$16.6</td>
<td>$16.45</td>
<td>$16.6</td>
<td>$210.00</td>
<td>$234.0K</td>
<td align="right">667</td>
<td align="right">446</td>
</tr>
<tr>
<td>RCL</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$16.6</td>
<td>$16.35</td>
<td>$16.6</td>
<td>$210.00</td>
<td>$141.1K</td>
<td align="right">667</td>
<td align="right">531</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$14.95</td>
<td>$14.35</td>
<td>$14.95</td>
<td>$220.00</td>
<td>$140.5K</td>
<td align="right">455</td>
<td align="right">183</td>
</tr>
<tr>
<td>RCL</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$23.2</td>
<td>$22.55</td>
<td>$23.25</td>
<td>$240.00</td>
<td>$102.3K</td>
<td align="right">326</td>
<td align="right">89</td>
</tr>
</tbody>
</table>
</p>
<h3>About Royal Caribbean Gr</h3>
<p>Royal Caribbean is the world's second-largest cruise company, operating 66 ships across five global and partner brands in the cruise vacation industry. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises. The selection of brands in the portfolio allows Royal to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in 2021 and plans to launch its new Celebrity River Cruise brand in 2027.</p>
<p>Having examined the options trading patterns of Royal Caribbean Gr, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of Royal Caribbean Gr</h3>
<ul>
<li>With a volume of 934,427, the price of RCL is down -0.62% at $224.0. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 30 days.</li>
</ul>
<h3>What Analysts Are Saying About Royal Caribbean Gr</h3>
<p>Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $272.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Loop Capital has elevated its stance to Buy, setting a new price target at $250.<br />
&#x2A; An analyst from Susquehanna persists with their Positive rating on Royal Caribbean Gr, maintaining a target price of $295. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Royal Caribbean Gr options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>


Spotlight on Royal Caribbean Gr: Analyzing the Surge in Options Activity

<p>Throughout the last three months, 4 analysts have evaluated Maravai LifeSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $4.62, a high estimate of $8.00, and a low estimate of $2.50. This current average represents a 44.0% decrease from the previous average price target of $8.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742929298_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Maravai LifeSciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$5.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.50</td>
<td>$8.00</td>
</tr>
<tr>
<td>Michael Ryskin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Catherine Schulte</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$3.00</td>
<td>$9.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Maravai LifeSciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Maravai LifeSciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Maravai LifeSciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Maravai LifeSciences's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MRVI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Maravai LifeSciences analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Get to Know Maravai LifeSciences Better</h2>
<p>Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.</p>
<h3>Maravai LifeSciences: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Maravai LifeSciences's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately <strong>-23.92%</strong> in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-46.35%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Maravai LifeSciences's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-7.8%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>-2.29%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Maravai LifeSciences's debt-to-equity ratio is below the industry average. With a ratio of <b>1.16</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

MRVI

Breaking Down Maravai LifeSciences: 4 Analysts Share Their Views

<p>In the last three months, 7 analysts have published ratings on Associated Banc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASB#NYSE">ASB</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $27.71, along with a high estimate of $30.00 and a low estimate of $26.00. A decline of 0.54% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742929272_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Associated Banc by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Daniel Tamayo</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$28.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Timur Braziler</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Karl Shepard</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Terry McEvoy</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Christopher Mcgratty</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$30.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>David George</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$26.00</td>
<td>$28.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Associated Banc. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Associated Banc compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Associated Banc's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Associated Banc's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ASB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Associated Banc analyst ratings.</strong></a></p>
<h2>All You Need to Know About Associated Banc</h2>
<p>Associated Banc-Corp is a bank holding company. The company through its subsidiaries provides a broad array of banking and nonbanking products and services to individuals and businesses. The company operates in three reportable segments; Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty and Community, Consumer, and Business segments.</p>
<h3>Associated Banc: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Associated Banc faced challenges, resulting in a decline of approximately <strong>-49.46%</strong> in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Financials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Associated Banc's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-264.76%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Associated Banc's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-3.78%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Associated Banc's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.38%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Associated Banc's debt-to-equity ratio surpasses industry norms, standing at <strong>0.61</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where Associated Banc Stands With Analysts

<p><a href="https://www.youtube.com/watch?v=Bm339t52XP4" title="https://www.youtube.com/watch?v=Bm339t52XP4">https://www.youtube.com/watch?v=Bm339t52XP4</a></p>


News

Econ #s

U.S. President Trump Say: Russia, Ukraine Will Get Together On Maritime Ceasefire

<p>6 analysts have expressed a variety of opinions on Pacific Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PACB#NASDAQ">PACB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $2.04, a high estimate of $2.50, and a low estimate of $1.50. Observing a downward trend, the current average is 30.14% lower than the prior average price target of $2.92. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742929238_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Pacific Biosciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$2.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$2.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.50</td>
<td>$1.75</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Mason Carrico</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$2.50</td>
<td>$2.50</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$1.75</td>
<td>$2.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Pacific Biosciences. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pacific Biosciences compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Pacific Biosciences's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Pacific Biosciences's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PACB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Pacific Biosciences analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>Discovering Pacific Biosciences: A Closer Look</h2>
<p>Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.</p>
<h3>A Deep Dive into Pacific Biosciences's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Pacific Biosciences's revenue growth over a period of 3 months has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately <strong>-32.79%</strong>. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Pacific Biosciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>6.04%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> Pacific Biosciences's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>0.49%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Pacific Biosciences's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.17%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.33</strong>, caution is advised due to increased financial risk.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


PACB

Assessing Pacific Biosciences: Insights From 6 Financial Analysts

<p>In the preceding three months, 35 analysts have released ratings for CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">15</td>
<td align="right">17</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">10</td>
<td align="right">12</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $430.89, with a high estimate of $506.00 and a low estimate of $370.00. Marking an increase of 6.65%, the current average surpasses the previous average price target of $404.03. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742929226_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of CrowdStrike Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gray Powell</td>
<td>BTIG</td>
<td>Announces</td>
<td>Buy</td>
<td>$431.00</td>
<td>-</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$425.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Joseph Gallo</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Buy</td>
<td>$425.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Adam Tindle</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Daniel Ives</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$395.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Jonathan Ruykhaver</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$440.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$435.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$425.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Peter Levine</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Trevor Walsh</td>
<td>Citizens Capital Markets</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$400.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Keith Bachman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$405.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$475.00</td>
<td>$506.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$405.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$450.00</td>
<td>$450.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$420.00</td>
<td>$420.00</td>
</tr>
<tr>
<td>Michael Walkley</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$420.00</td>
<td>$370.00</td>
</tr>
<tr>
<td>Brian Essex</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$450.00</td>
<td>$418.00</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Roger Boyd</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$450.00</td>
<td>$396.00</td>
</tr>
<tr>
<td>Tal Liani</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$420.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$506.00</td>
<td>$372.00</td>
</tr>
<tr>
<td>Adam Borg</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$475.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Hamza Fodderwala</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$429.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$460.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$450.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$480.00</td>
<td>$395.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$430.00</td>
<td>$390.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$370.00</td>
<td>$300.00</td>
</tr>
<tr>
<td>Fatima Boolani</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$420.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Matthew Hedberg</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$420.00</td>
<td>$365.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CrowdStrike Holdings. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of CrowdStrike Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of CrowdStrike Holdings's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of CrowdStrike Holdings's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CRWD/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on CrowdStrike Holdings analyst ratings.</strong></a></p>
<h2>About CrowdStrike Holdings</h2>
<p>CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.</p>
<h3>CrowdStrike Holdings's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining CrowdStrike Holdings's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>25.22%</strong> as of 31 January, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> CrowdStrike Holdings's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-8.72%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> CrowdStrike Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-2.91%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> CrowdStrike Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-1.12%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> CrowdStrike Holdings's debt-to-equity ratio is below the industry average. With a ratio of <b>0.24</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CRWD

Beyond The Numbers: 35 Analysts Discuss CrowdStrike Holdings Stock

<p>Vital Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTLE#NYSE">VTLE</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $33.67, with a high estimate of $49.00 and a low estimate of $23.00. A 11.14% drop is evident in the current average compared to the previous average price target of $37.89. </p>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742929211_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Vital Energy by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$24.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Zach Parham</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$23.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>John Freeman</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$24.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Hanwen Chang</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$49.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Vital Energy. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Vital Energy compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Vital Energy's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/VTLE/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Stay up to date on Vital Energy analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.</p>
<h2>All You Need to Know About Vital Energy</h2>
<p>Vital Energy is an independent energy company. Its business is focused on the acquisition, exploration, and development of oil and natural gas properties in the Permian Basin of West Texas. The Company has identified one operating segment: exploration and production.</p>
<h3>Unraveling the Financial Story of Vital Energy</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Vital Energy's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>20.21%</strong> as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Energy sector.</p>
<p><strong>Net Margin:</strong> Vital Energy's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-67.26%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Vital Energy's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-12.49%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Vital Energy's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-5.93%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Vital Energy's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>0.95</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


VTLE

Forecasting The Future: 9 Analyst Projections For Vital Energy

U.S. President Trump Says: We've Made a Lot of Progress On Ukraine; We Are In Deep Discussions With Russia, Ukraine And It's Going Well; Making A Lot Of Progress On Middle East

<p><strong>J.P. Morgan </strong>analyst Zach Parham <a target="_blank" href="https://www.benzinga.com/quote/CIVI/analyst-ratings" rel="noreferrer noopener">retained a Neutral rating</a> on <strong>Civitas Resources, Inc. </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIVI#NYSE">CIVI</a>) with a price forecast of $49.</p>
<p>The analyst writes that CIVI&#8217;s goal remains consistent with its fourth-quarter update, maintaining its focus on debt reduction over share buybacks.</p>
<p>The analyst notes that the company aims to generate FCF and reduce debt by $800 million in FY25, which he sees as achievable at current strip pricing.</p>
<p>Parham says asset sales remain a focus for the company, with a goal of over $300 million for FY25. Media reports suggest CIVI is considering selling its DJ Basin position for over $4 billion.</p>
<p>The analyst notes that a larger DJ transaction is possible, though the company is unlikely to sell at a steep discount and he awaits further clarity from management on the earnings call.</p>
<p>The analyst estimates cash flow per share of $7.39 for the first quarter of FY25, a touch below the street estimates of $7.47 after marking to market for commodity prices.</p>
<p>Also, Parham sees first-quarter oil production of 143.2 MBo/d, in line with the consensus estimates of 143.1 MBo/d and EBITDA estimate of $799 million, broadly at par with the consensus of $797 million.</p>
<p>For FY25, the analyst estimates oil production of 152.8 MBo/d on $1.85 billion of capex, in-line with the street estimates and CIVI&#8217;s guidance.</p>
<p>Investors can gain exposure to the stock via <strong>First Trust Energy AlphaDEX Fund</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FXN#NYSE">FXN</a>) and <strong>VictoryShares Small Cap Free Cash Flow ETF </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFLO#NASDAQ">SFLO</a>).</p>
<p><strong>Price Action: </strong>CIVI shares are down 0.52% at $36.24 at the last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/25/03/44473549/pony-ai-q4-revenue-slumps-nearly-30-as-robotaxi-sales-decline-loss-widens" target="_blank" rel="noreferrer noopener">Pony AI Q4: Revenue Slumps Nearly 30% As Robotaxi Sales Decline, Loss Widens</a></strong></li>
</ul>
<p><em>Photo via Shutterstock.</em></p>


Analyst Color

Equities

Mid Cap

Price Target

Reiteration

Trading Ideas

CIVI

SFLO

Civitas Resources Focuses On Debt Paydown, Asset Sales For FY25 Growth: Analyst

WIIM

BLNE

Beeline Holdings shares are trading higher after the company announced its CEO invested an additional $900,000 into the company's ongoing Series G convertible equity offering.

<p>Stifel initiated coverage on Monday on <strong>Crinetics Pharmaceuticals Inc </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNX#NASDAQ">CRNX</a>), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and <a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">endocrine-related tumors</a>.</p>
<p>Crinetics&#8217; lead development candidate, Paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors.</p>
<p>The Paltusotine U.S. application for acromegaly is under FDA review. The Prescription Drug User Fee Act (PDUFA) target action date for the Paltusotine NDA for the treatment and maintenance therapy of acromegaly is <a href="https://www.benzinga.com/pressreleases/25/02/g44024626/crinetics-pharmaceuticals-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides" target="_blank" rel="noreferrer noopener">Sept. 25, 2025</a>.</p>
<p>Analyst <strong>Alex Thompson </strong>writes Paltusotine can potentially disrupt the treatment paradigm in Acromegaly and Carcinoid Syndrome and achieve around $2 billion in combined peak global sales.</p>
<p>Stifel has initiated with a Buy rating and a <a target="_blank" href="https://www.benzinga.com/quote/CRNX/analyst-ratings" rel="noreferrer noopener">price target of $60</a>.</p>
<p>The company&#8217;s second pipeline asset, Atumelnant, is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing&#8217;s syndrome.</p>
<p>In January, Crinetics Pharmaceuticals released topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42908820/crinetics-announces-positive-topline-results-from-phase-2-trial-of-atumelnant-in-congenital-adrena" rel="noreferrer noopener">investigational atumelnant</a>.</p>
<p>For all doses, treatment with atumelnant resulted in a rapid, substantial, and sustained statistically significant reduction in A4 levels, the key biomarker for disease control.</p>
<p>The analyst notes that while early data for Atumelnant looks promising and stands out, concerns over temporary liver issues have drawn more attention. However, positive regulatory decisions are a good sign.</p>
<p>Stifel also says that while uptake in Carcinoid Syndrome may be slower until Crinetics generates PFS data, there is mechanistic translation and model modest uptake over time, translating to around $1.4 billion in peak global sales.</p>
<p>&#8220;Bottom line, with the stock now well-off 2024 highs, we can largely support today&#8217;s valuation with Paltusotine alone and see confirmation of Atumelnant&#8217;s efficacy/safety in CAH and progression of the broader pipeline as compelling upside drivers along with a strong a balance sheet and increasing investor interest in endocrinology,&#8221; analyst Thompson writes.</p>
<p><strong>CRNX Price Action:</strong> Crinetics Pharmaceuticals stock is down 2.62% at $35 at publication Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/03/44474207/canadian-solar-posts-wider-q4-loss-reaffirms-2025-outlook-amid-fierce-industry-headwinds" target="_blank" rel="noreferrer noopener">Canadian Solar Posts Wider Q4 Loss, Reaffirms 2025 Outlook Amid Fierce Industry Headwinds</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Biotech

Health Care

Initiation

CRNX

Crinetics Pharmaceuticals Analyst Sees Around 70% Upside For Stock, Cites More Investor Interest In Endocrinology

<p>Blockchain industry group The Digital Chamber on Tuesday unveiled a comprehensive policy roadmap urging U.S. lawmakers to adopt sweeping reforms that harness blockchain technology to modernize the nation's financial systems, bolster national security, and secure America's position as a <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44450232/white-house-says-gold-reserves-may-be-used-to-purchase-bitcoin">global innovation leader</a>.</p>
<p>The U.S. Blockchain Roadmap outlines recommendations across six pillars, including improving financial stability with digital assets, safeguarding decentralization, and advancing energy security through <strong>Bitcoin </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining. </p>
<p>The framework also calls for legislative action such as passing stablecoin laws, reforming the Federal Reserve&#8217;s master account process, and updating privacy protections under the Bank Secrecy Act.</p>
<p>"For the first time, we have the political will and alignment necessary to lead in the digital asset era," said <strong>Perianne Boring</strong>, Founder and outgoing CEO of The Digital Chamber, who will transition to Chair of the Board in April. </p>
<p>"This roadmap provides the strategic direction to turn momentum into action and ensure the United States leads the world in blockchain innovation."</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44473477/blackrock-brings-tokenized-money-market-fund-buidl-to-solana">BlackRock Brings Tokenized Money Market Fund &#8216;BUIDL&#8217; To Solana</a></strong></p>
<p>The policy blueprint comes amid a leadership transition at the Chamber. </p>
<p>Incoming CEO <strong>Cody Carbone</strong>, currently President, emphasized the urgency of the moment. "This roadmap is a call to action," Carbone said. "It lays out a clear plan for how policymakers can embrace blockchain to solve the U.S.' most pressing issues."</p>
<p>Among its headline proposals, the roadmap advocates for:</p>
<ul>
<li>The BITCOIN Act and a national stablecoin framework</li>
<li>The formation of a self-regulatory organization for digital assets</li>
<li>Investment in R&amp;D funding to integrate blockchain into government operations</li>
<li>Reforms to modernize the U.S. banking system and unlock access to blockchain-based financial services.</li>
</ul>
<p><strong>Read Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/25/03/44472657/strategy-aims-for-more-bitcoin-with-strife-stock-how-does-it-work">Strategy Aims For More Bitcoin With &#8216;Strife&#8217; Stock: How Does It Work?</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$BTC

Digital Chamber Urges Congress To Act On Blockchain For National Security, Financial Innovation, Energy Independence

<p>On Sunday, human genetics and biotechnology company&nbsp;<strong>23andMe Holding Co</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) voluntarily filed for Chapter 11 bankruptcy to enable a sale process to <a target="_blank" href="https://www.benzinga.com/25/03/44456578/why-dna-test-provider-23andmes-stock-is-plunging-today" rel="noreferrer noopener">maximize its business value</a>.</p>
<p>The move follows the recent&nbsp;rejection of a non-binding acquisition&nbsp;offer from CEO&nbsp;<strong>Anne Wojcicki</strong>&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44451644/23andme-initiates-voluntary-chapter-11-process-to-maximize-stakeholder-value-through-court-supervi" rel="noreferrer noopener">and her affiliates</a>. In November,&nbsp;<strong>23andMe </strong>had announced a business restructuring to streamline&nbsp;<a target="_blank" href="https://www.benzinga.com/general/health-care/24/11/41914499/struggling-genetic-testing-company-23andme-to-lay-off-40-of-its-workforce-discontinues-all-therapeutic-programs" rel="noreferrer noopener">operations and reduce costs</a>.</p>
<p>Customers who have shared their DNA with the company now risk having their genetic data sold to the highest bidder due to its bankruptcy, raising concerns about privacy and legal protections.</p>
<p>The Bloomberg <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-03-24/23andme-s-bankruptcy-puts-15-million-users-dna-info-on-auction-block?srnd=homepage-americas&amp;sref=TBDibEcD" rel="noreferrer noopener">report</a> says 23andMe has proposed a May 14 auction to sell its assets. Founded in 2006, 23andMe said in court papers that the data represents "one of the world's largest crowdsourced platforms for genetic research."</p>
<p>In a <a target="_blank" href="https://blog.23andme.com/articles/open-letter" rel="noreferrer noopener">note</a> to customers, 23andMe said that the "Chapter 11 filing does not change how we store, manage, or protect customer data." The company boasts a database of 15 million customers globally.</p>
<p>The company added that customers will have full access to their accounts, genetic reports, and any stored data during the process.</p>
<p>On Tuesday, New York Attorney General Letitia James <a target="_blank" href="https://ag.ny.gov/press-release/2025/attorney-general-james-urges-23andme-customers-contact-company-delete-data" rel="noreferrer noopener">issued</a> a consumer alert to customers of 23andMe, providing instructions on how to delete their personal data and destroy any samples of genetic material held by the company.</p>
<p>Bloomberg report, citing a court filing, outlined that bidders must state in writing that they comply with the company's privacy practices, "which do not restrict the transfer of personally identifiable information of the debtors' customers in connection with a bankruptcy, merger, acquisition, reorganization, or sale of assets."</p>
<p>"We are watching this bankruptcy filing closely and expect to be actively engaged to ensure sensitive records are protected and 23andMe is held accountable," Connecticut Attorney General William Tong <a target="_blank" href="https://portal.ct.gov/ag/press-releases/2025-press-releases/attorney-general-tong-issues-consumer-alert-regarding-23andme-bankruptcy" rel="noreferrer noopener">said</a> on Monday.</p>
<p>In 2023, 23andMe learned that a threat actor accessed several individual 23andMe.com accounts through credential stuffing. The data breach&nbsp;<a target="_blank" href="https://blog.23andme.com/articles/addressing-data-security-concerns?tblci=GiCUX7wvU_AgmIIiQduNYr6JQuJQLy6SZJGvpyeZuCzyqiCN1Vco2-XEnaS03LIXMO-ISg" rel="noreferrer noopener">occurred</a> in April 2023, and the company learned about the incident in October 2023.</p>
<p>The company&nbsp;<a target="_blank" href="https://fingfx.thomsonreuters.com/gfx/legaldocs/zdpxqyqkqvx/frankel-23andme--prelimsettlementmotion.pdf" rel="noreferrer noopener">settled</a> the lawsuits with $30 million related to the breach. A law firm representing around 5,000 customers of genetic testing company 23andMe has raised objections to a proposed $30 million class action settlement, arguing the settlement is intentionally designed to <a target="_blank" href="https://www.benzinga.com/news/24/10/41146410/legal-battle-brews-over-23andmes-customer-data-breach-settlement-and-arbitration-claimants" rel="noreferrer noopener">undermine claimants' rights</a>.</p>
<p><strong>Price Action: </strong>ME stock is down 11.7% at $0.64 at the last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/25/03/44476972/alliance-entertainment-wins-bid-to-acquire-diamond-comic-distributors-stock-gains" target="_blank" rel="noreferrer noopener">Alliance Entertainment Wins Bid to Acquire Diamond Comic Distributors, Stock Gains</a></strong></li>
</ul>
<p><em>Photo via Shutterstock</em></p>


Movers

23andMe's Bankruptcy Sparks Privacy Concerns Over Genetic Database Of 15 Million Customers

<p><strong>Unity Software's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) short percent of float has risen 11.57% since its last report. The company recently reported that it has <strong>31.90 million shares sold short</strong>, which is 8.1% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 1.24 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>Unity Software Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742928325_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Unity Software has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Unity Software's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Unity Software's peer group average for short interest as a percentage of float is 6.17%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

Is Unity Software Gaining or Losing Market Support?

<p><strong>TKO Group Holdings's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>) short percent of float has fallen 3.11% since its last report. The company recently reported that it has <strong>7.09 million shares sold short</strong>, which is 9.02% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 4.23 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>TKO Group Holdings Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742928320_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for TKO Group Holdings has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing TKO Group Holdings's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, TKO Group Holdings's peer group average for short interest as a percentage of float is 7.66%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


How Is The Market Feeling About TKO Group Holdings?

<p><strong>M&amp;T Bank's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) short percent of float has risen 30.12% since its last report. The company recently reported that it has <strong>4.68 million shares sold short</strong>, which is 3.24% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 3.43 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>List of the most shorted stocks</strong></a></p>
<h3>M&amp;T Bank Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2025/1742928315_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for M&amp;T Bank has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing M&amp;T Bank's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, M&amp;T Bank's peer group average for short interest as a percentage of float is 3.86%, which means the company has <strong>less</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into M&T Bank's Recent Short Interest

MGRX

Mangoceuticals shares are trading lower. The company announced that it entered into a Master Distribution Agreement to secure the exclusive licensing and distribution rights for Diabetinol within the United States and Canada.

Comments

ATRenew

Actualités

Dernières nouvelles pour ATRenew (NYSE:RERE) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL